EZH2 also serves as a critical therapeutic target of human malignancies including hematopoietic cancers (Bödör et al., 2013; Chang and Hung, 2012; Kim and Roberts, 2016). The gene discussed is EZH2; the disease is hematopoietic and lymphoid cell neoplasm.